AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01904643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given PO
Study NCT01904643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride
Description: Given IV
Study NCT01904643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT01904643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study NCT02549352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO43204 gel
Study NCT02549352 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle gel
Study NCT04316078 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: patient engagement platform
Description: 1. Allows patients to receive the action plan as educational videos on demand.~2. Allows patients to report side effects and quality of life via questionnaires and receive immediate targeted education based on the predefined action plan.
Study NCT03177811 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACETAZOLAMIDE oral capsule
Description: Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
Study NCT03177811 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
Study NCT06519461 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-centered teaching model
Description: The program comprised two parts: (1) Didactic lessons: and (2) Hands-on practice. The didactic lessons were designed to prepare interns' knowledge and skills. The hands-on practice were designed to provide opportunities of family-centered experience to work with caregivers and children.
Study NCT01174017 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Iodine 125 standard loose brachytherapy seeds
Description: radioactivity 0.4 U per seed, prescribed dose 144 Gy
Study NCT01174017 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: AnchorSeed Iodine 125 brachytherapy prostate implant
Description: activity 0.4 U per seed, prescribed dose 144 Gy
Study NCT03950687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Human Erythropoiesis Injection (CHO cell)
Description: rHuEPO is a recombinant human erythropoietin with the same biological effects as natural erythropoietin
Study NCT03950687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Erythropoiesis Stimulating Protein Injection(CHO cell)
Description: rESP is a high glucose medium and long-acting recombinant protein products, containing 165 amino acids by adding 3 glycosylation sites
Study NCT00159575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin / Placebo treatment for 4 months
Description: M: Metformin 2000mg daily- 12-14 weeks of pretreatment + metformin 2000mg daily through conventional IVF ending on the day of pregnancy test; IE. 14 days after embryo transfer. P: Or identical placebo treatment for the same period
Study NCT01672099 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: nutrient enriched product
Description: The intervention in this study consists of the consumption of two nutrient enriched yoghurt products. The participants consume the study products twice a day during 12 weeks, one yoghurt product (250 ml) during breakfast and one yoghurt product (250 ml) during dinner.
Study NCT01672099 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: basic dairy product
Description: The intervention in this study consists of the consumption of two basic yoghurt products. The participants consume the basic yoghurt products twice a day during 12 weeks, one yoghurt product (250 ml) during breakfast and one yoghurt product (250 ml) during dinner.
Study NCT04575818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG4059 oral suspension
Description: GLPG4059 for oral administration
Study NCT04575818 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral suspension
Study NCT04575818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG4059 tablet
Description: GLPG4059 for oral administration
Study NCT00438854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Taken orally once daily. Participants may continue on study treatment as long as there is no disease progression or serious side effects.
Study NCT02852941 — intervention group
Intervention type: DEVICE
Intervention: CardioScreen 1000
Description: Haemodynamic Measurement System, Medis Impedance cardiography (ICG)
Study NCT02852941 — intervention group
Intervention type: DEVICE
Intervention: Tanita 418- Bioelectrical impedance analysis
Description: The device measured the size of total body water (TBW), fat mass (FM%), visceral fat%, fat free mass (FFM), and basal metabolic rate (BMR) (kcal).
Study NCT02590601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bromocriptine
Study NCT02590601 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Guideline-driven medical therapy (GDMT)
Study NCT02590601 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Guideline-driven medical therapy (GDMT)
Study NCT00303446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dutasteride
Description: Dutasteride 0.5 mg/day
Study NCT00303446 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo
Study NCT01556776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: placebo or lenalidomide 5 mg daily on days 1-28 of the first 28-day cycle. If the 5 mg dose level is well tolerated, escalation to 10 mg daily on days 1-28 of cycle 2-6 is permitted; further escalations starting with the 7th cycle and up to the 12th cycle to 15 mg daily is permitted. If after 12 cycles of treatment subjects still present with MRD levels of ≥ 10-4 in peripheral blood and previous dose levels are well tolerated, starting with the 13th cycle up to progression 20 mg daily is permitted. If after 18 cycles of treatment for subjects still present with MRD.levels of ≥ 10-4 in peripheral blood and previous dose levels are well tolerated, starting with the 19th cycle up to progression 25 mg daily is permitted. 25 mg is the maximal daily dose of lenalidomide
Study NCT01556776 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo or lenalidomide 5 mg daily on days 1-28 of the first 28-day cycle. If the 5 mg dose level is well tolerated, escalation to 10 mg daily on days 1-28 of cycle 2-6 is permitted; further escalations starting with the 7th cycle and up to the 12th cycle to 15 mg daily is permitted. If after 12 cycles of treatment subjects still present with MRD levels of ≥ 10-4 in peripheral blood and previous dose levels are well tolerated, starting with the 13th cycle up to progression 20 mg daily is permitted. If after 18 cycles of treatment for subjects still present with MRD.levels of ≥ 10-4 in peripheral blood and previous dose levels are well tolerated, starting with the 19th cycle up to progression 25 mg daily is permitted. 25 mg is the maximal daily dose of lenalidomide
Study NCT00679263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MN-221
Description: Initial dose: 16 μg/min for 15 minutes followed by 8 μg/min for 105 minutes (2-hour infusion with a total dose of 1,080 μg)
Study NCT00679263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MN-221
Description: Subsequent dose: 30 μg/min for 15 minutes followed by 15 μg/min for 45 minutes (1-hr infusion with a total dose of 1,125 μg).
Study NCT00679263 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intravenous infusion with dosing volume equivalent to active treatment.
Study NCT03202797 — intervention group
Intervention type: OTHER
Intervention: audiometric tests
Description: tone and speech audiometry
Study NCT03202797 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: APHAB (Abbreviate Profile of Hearing Aid Benefit), HISQUI (Hearing Implant Sound Quality Index), Munich music questionnaire
Study NCT03202797 — intervention group
Intervention type: OTHER
Intervention: Settings of cochlear implants
Description: pitch matching, evolutionary algorithm setting
Study NCT04034420 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online training platform
Description: Self-paced training and learning materials in relation to family services
Study NCT05454059 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: HbA1c Level
Description: Measurement of HbA1c levels from blood tests
Study NCT03484832 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Walter Ritter Ethyl Chloride Spray
Description: Participants receive an application of EMLA or placebo cream at the needle electrode insertion site 60 minutes before needle insertion, and a self adhering dressing is placed over the site. After 60 minutes, the dressing and cream are removed from the site, then the insertion site is sprayed from a distance of 30 cm for 5 seconds or until the skin was blanched, then intra-articular injection of shoulder is performed.
Study NCT03484832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Spray
Description: Participants receive an application of EMLA or placebo cream at the needle electrode insertion site 60 minutes before needle insertion, and a self adhering dressing is placed over the site. After 60 minutes, the dressing and cream are removed from the site, then the insertion site is sprayed using placebo spray (Evain Eau Minerale Naturelle, a pure water spray with hydrocarbon propellant), then intra-articular injection of shoulder is performed.
Study NCT03484832 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Spray
Description: Participants receive an application of EMLA or placebo cream at the needle electrode insertion site 60 minutes before needle insertion, and a self adhering dressing is placed over the site. After 60 minutes, the dressing and cream are removed from the site, then the insertion site is sprayed using placebo spray (Evain Eau Minerale Naturelle, a pure water spray with hydrocarbon propellant), then intra-articular injection of shoulder is performed.
Study NCT03484832 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cream
Description: Participants receive an application of placebo cream at the needle electrode insertion site 60 minutes before needle insertion, and a self adhering dressing is placed over the site. After 60 minutes, the dressing and cream are removed from the site, then the insertion site is sprayed using Walter Ritter Ethyl chloride spray or placebo spray, then intra-articular injection of shoulder is performed.
Study NCT03484832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Cream
Description: Participants receive an application of placebo cream at the needle electrode insertion site 60 minutes before needle insertion, and a self adhering dressing is placed over the site. After 60 minutes, the dressing and cream are removed from the site, then the insertion site is sprayed using Walter Ritter Ethyl chloride spray or placebo spray, then intra-articular injection of shoulder is performed.
Study NCT03484832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMLA Cream
Description: Participants receive an application of EMLA cream at the needle electrode insertion site 60 minutes before needle insertion, and a self adhering dressing is placed over the site. After 60 minutes, the dressing and cream are removed from the site, then the insertion site is sprayed using Walter Ritter Ethyl chloride spray or placebo spray, then intra-articular injection of shoulder is performed.
Study NCT03351556 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Arm 1
Description: Participants in this arm will receive the standard HIV primary care services according to Tanzania's National Guidelines for the Management of HIV and AIDS plus the opportunity to earn 10,000 TZS/month conditional on visit attendance.
Study NCT03351556 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Arm 2
Description: Participants in this arm will receive the standard HIV primary care services according to Tanzania's National Guidelines for the Management of HIV and AIDS plus the opportunity to earn 22,500 TZS/month conditional on visit attendance.
Study NCT05454059 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HbA1c Level
Description: Measurement of HbA1c levels from blood tests
Study NCT02687217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxygen
Description: Hyperoxygenation ≥50% of oxygen by mask(non-rebreathing) was given through out the surgery.~Received 6L/min of oxygen through venturimask upto 2 hours in post operative period.~Hyperoxygenation refers to provision of ≥50% of oxygen by mask(non-rebreathing) through out the surgery.
Study NCT03761940 — intervention group
Intervention type: OTHER
Intervention: EQ5D questionnaire and a demographic questionnaire
Description: questionnaires
Study NCT00822900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Following a one hour loading dose of 0.714 mg/kg per infusion pump through a dedicated IV line, the study drug (progesterone or placebo) will be administered as a continuous intravenous infusion at 0.5 mg/kg/hr for 71 hours, then tapered over an additional 24 hours. To simplify the infusion protocol, a weight based dosing table will be used by the on-sight pharmacy to mix the correct dose for a 10 cc/hour continuous infusion over the 71 hour steady state period followed by three additional 8-hour decrements (7.5 cc/hr-5.0 cc/hr-2.5 cc/hr) to zero, for a total treatment duration of 96 hour. The progesterone/placebo will be combined with a 20% Intralipid mixture for infusion.
Study NCT00822900 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo stock solution is the ethanol diluent required for dissolving progesterone. The volume of placebo to be mixed with intralipid is based on the mg/kg/hr volume. Using an infusion pump through a dedicated IV line - a one hour loading dose of placebo plus intralipid is administered as a continuous intravenous infusion for 71 hours, then tapered over an additional 24 hours.
Study NCT01939249 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Abbott Laboratories Xience
Study NCT01939249 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biotronik Orsiro
Study NCT00895245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fosaprepitant dimeglumine
Description: Given IV
Study NCT00895245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT00895245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palonosetron hydrochloride
Description: Given IV
Study NCT00895245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given IV and orally
Study NCT00895245 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Living Index-Emesis Questionnaire
Description: Ancillary studies
Study NCT00895245 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emesis Diary
Description: Ancillary studies
Study NCT00895245 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Undergo radiotherapy
Study NCT00509743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous diclofenac sodium (DIC075V)
Description: High dose Diclofenac
Study NCT00509743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous diclofenac sodium (DIC075V)
Description: Low Dose Diclofenac
Study NCT01628367 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally Traumatic Tooth Extraction
Description: The surgeon will perform a minimally traumatic tooth extraction in the following fashion. Intrasulcular incisions will be performed with at 15-C scalpel around the tooth to be extracted.~A periotome will then be introduced into the periodontal ligament space in order to sever the subcrestal attachment and expand the periodontal ligament space. Elevators will be used to initiate luxation of teeth. After significant mobility has been achieved through elevation, forceps will be used only to deliver the tooth. Finally, the socket will be curetted to remove all granulomatous tissue and irrigated with sterile isotonic saline solution.
Study NCT02570581 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plain jelly control
Study NCT02570581 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Plain jelly control
Study NCT02570581 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Paracetamol
Study NCT01628367 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally Traumatic Tooth Extraction
Description: The surgeon will perform a minimally traumatic tooth extraction in the following fashion. Intrasulcular incisions will be performed with at 15-C scalpel around the tooth to be extracted.~A periotome will then be introduced into the periodontal ligament space in order to sever the subcrestal attachment and expand the periodontal ligament space. Elevators will be used to initiate luxation of teeth. After significant mobility has been achieved through elevation, forceps will be used only to deliver the tooth. Finally, the socket will be curetted to remove all granulomatous tissue and irrigated with sterile isotonic saline solution.
Study NCT01628367 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate Implant Placement
Description: A threaded titanium alloy implant with an internal hex connection and a Resorbable Blast Texturing (RBT) surface (Tapered Internal® Implant System, Biohorizons, Inc., Birmingham, AL, USA) will be placed using a surgical guide. Implant diameter of 3.8mm with lengths of either 12 or 15mm will be used. Implants will be placed approximately 3-4mm below the free gingival margin or 2-3mm below the cemento-enamel junction of adjacent teeth.
Study NCT01628367 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immediate Implant Placement
Description: A threaded titanium alloy implant with an internal hex connection and a Resorbable Blast Texturing (RBT) surface (Tapered Internal® Implant System, Biohorizons, Inc., Birmingham, AL, USA) will be placed using a surgical guide. Implant diameter of 3.8mm with lengths of either 12 or 15mm will be used. Implants will be placed approximately 3-4mm below the free gingival margin or 2-3mm below the cemento-enamel junction of adjacent teeth.
Study NCT01628367 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bone Graft Placement
Description: Circumferential defects or dehiscences around the immediately placed implant will be grafted. enCore™ Combination Allograft (Osteogenics Biomedical, Lubbock, Texas, USA) will be used as the bone graft material.
Study NCT00831506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: digoxin
Description: digoxin once daily (0.125 mg QD) plus placebo three times daily (TID), 8 hours apart for 14 days.
Study NCT00831506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: digoxin
Description: digoxin once daily (0.125 mg QD) for 14 days.
Study NCT00831506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimebon
Description: Dimebon three times a day, 8 hours apart for 14 days (10 mg TID on Days 1-7 and 20 mg TID on Days 8-14).
Study NCT01802424 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Friends program
Description: The Friends program is a ten weeks group interventions based on principles from Cognitive Behavioural Therapy aimed at ameliorating symptoms of anxiety and depression in children and adolescents. There are age-specific versions of the manual, one for children 8-12 years and one for adolescents 12-15 years.
Study NCT00690404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2066
Description: single oral dose
Study NCT02408913 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-EBOMVA079-00-VP (MVA-EbolaZ)
Description: Ebola Modified Vaccinia Virus Ankara Vaccine
Study NCT02570581 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Apple compote Paracetamol
Study NCT02570581 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple compote Furosemide
Study NCT02408913 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-EBOADC069-00-VP (cAd3-EBO)
Description: Ebola Chimpanzee Adenovirus Vector Vaccine
Study NCT04255225 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking for 10 minutes
Description: Participants will walk on a treadmill for 10 minutes at a moderate intensity.
Study NCT04255225 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking for 20 minutes
Description: Participants will walk on a treadmill for 20 minutes at a moderate intensity.
Study NCT04255225 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking for 30 minutes
Description: Participants will walk on a treadmill for 30 minutes at a moderate intensity.
Study NCT01553266 — intervention group
Intervention type: BEHAVIORAL
Intervention: Mobile Diabetes Education Teams intervention
Description: A MDET (one Registered Nurse and Registered Dietician) supports primary care physicians by providing diabetes management education to the PCPs' patients onsite, one to four times a month based on patient volume.
Study NCT02535221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin+TAM+AI
Description: Goserelin 3.6mg subcutaneous injection per 4 weeks, for 16-20weeks. TAM 10mg oral twice a day for the first four weeks(to wait the Goserelin start to work in body) than change to AI 1mg oral once a day with Goserelin for the next 12-16 weeks.